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Epstein-Barr virus (EBV)-related micoRNAs (miRNAs), BamHI-A rightward transcripts
(BART)-miRNAs, are released in a stable form from viable cells, which are abundant in
patients with EBV-positive nasopharyngeal carcinoma (NPC). We estimated copy numbers
of circulating miR-BART2-5p, miR-BART17-5p, and miR-BART18-5p as well as BamHI-W
DNA as biomarkers.
Materials and Methods
Serums from 31 EBV-positive (confirmed by in situ hybridization for EBV-encoded small
RNAs) NPC patients and 40 non-NPC controls were analyzed. Among the 31 NPC patients,
serums at the initial diagnosis and three months after treatment were obtained from 20
patients, and serums only at three months after treatment were obtained from 11 patients.
Results
The sensitivity/specificity of circulating BamHI-W DNA, miR-BART2-5p, miR-BART17-5p,
and miR-BART18-5p for the diagnosis of NPC before treatment were 100 / 100, 85 / 85, 60
/ 95, and 25 / 100%, respectively. For BamHI-W DNA, NPC patients with stage IV disease
had significantly higher copy numbers than those with I-III. Copy numbers decreased signif-
icantly post-treatment. In contrast, copy numbers of the three BART-miRNAs showed no
significant correlation with the clinical stage at diagnosis or any significant post-treatment
change. After treatment, BamHI-W DNA and miR-BART17-5p were detected in 5 and 6
cases out of 11 patients with recurrent or residual tumors, respectively. However, BamHI-
W DNA and miR-BART17-5p were absent in all 20 patients without relapse or residual
tumors.
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Conclusion
The copy number of circulating BamHI-W DNA is a more useful biomarker for the initial
diagnosis of NPC than the three BART-miRNAs examined. Post-treatment detection of
miR-BART17-5p is a potential biomarker of a poor prognosis.
Introduction
Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia, but rare
in most countries including Japan [1,2,3]. In addition to its geographic and population variations,
NPC has some unique features. Etiologically, latent infection by Epstein-Barr virus (EBV) causes
most cases of the non-keratinizing carcinoma differentiated type and non-keratinizing carcinoma
undifferentiated type of NPCs, categorized as World Health Organization (WHO)-2A orWHO-
2B NPC [4]. However, the contribution of EBV to the keratinizing squamous cell carcinoma,
WHO-1, has been controversial. NPC generally shows the EBV-gene expression profile of type II
latency; EBV-determined nuclear antigen-1, latent membrane protein (LMP)-1, LMP2, EBV-
encoded small RNAs (EBERs), and BamHI-A rightward transcript (BART)-microRNAs (miR-
NAs) [5]. Clinically, NPC is highly invasive and metastatic, and, therefore, most NPC patients
are diagnosed at an advanced stage [6,7]. Because of the anatomical features, the disease is not
suitable for surgical resection [8]. Thus, radiotherapy plays a central role in the locoregional con-
trol of NPC [9,10]. Another characteristic of NPC is that metastasis to regional and/or distant
sites is more common than for other carcinomas of the head and neck. Therefore, chemotherapy
plays an important role in improving the treatment outcome [11].
We have been performing chemotherapy and radiotherapy alternately: first, chemotherapy,
consisting of 5-FU (800 mg/m2/day on days 2–5) and cisplatin (100 mg/m2/day on day 6), is
administered, and then a wide field of radiotherapy (36 Gy/ 20 fractions), chemotherapy, a
shrinking field of radiotherapy (34 Gy/17 fractions), and chemotherapy [12]. Full-course treat-
ment has been completed in 76.1% of patients, with overall and progression-free survival rates at
5 years of 78.04 and 68.74%, respectively. The data are at least comparable to those of the che-
moradiotherapy arm of the American Intergroup Study 0099, which has been a mainstay in NPC
treatment [11]. However, 30.1% of patients still develop recurrent or residual diseases. Therefore,
there is still room to administer adjuvant chemotherapy (AC) following alternating chemora-
diotherapy. It is inevitable that adding AC for all cases would increase treatment toxicity. Thus,
biomarkers that can be used reliably to extract high-risk patients for recurrence and/or residual
diseases are expected after treatment, so that we can solely performAC for selected patients.
The consistent association betweenNPC and EBV-infection permits EBV-related factors to
serve as biomarkers of NPC [13,14,15,16]. The EBV viral capsid antigen (VCA)/Immunoglob-
ulin A (IgA) antibody titer has been used for NPC screening.However, the antibody titer is
maintained at a high level after treatment in some NPC patients maintaining complete remis-
sion [14]. Therefore, the EBV VCA/IgA titer is not recommended as a reliable biomarker of
the prognosis after treatment or for monitoring relapse. Now, quantitative analyses of copy
numbers of circulating cell-free EBV-DNAs, especially BamHI-WDNA, by the quantitative
polymerase chain reaction (qPCR) provide the most reliable biomarkers for NPC, the sensitiv-
ity and specificity of which are 93–96 and 92–100% for primary diagnosis, respectively [14].
The EBV-DNA loads at the initial diagnosis are correlated with the clinical stage and progno-
sis, and the detection of EBV-DNA after treatment was shown to be a predictive factor for
recurrence and/or a residual tumor [14,17]. The source of cell-free EBV-DNA present in
serumor plasma has been suggested to be derived from apoptotic NPC cells shed into the
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blood stream [14,15]. As the DNA loads are correlated with the clinical stage of NPC, estimated
EBV-DNA copy numbers reflect the tumor volume at diagnosis and/or after treatment, but not
the biological activity of viable tumor cells.
BART-miRNAs are non-codingmiRNAs expressed abundantly in NPC cells [18]. EBV
encodes 22 BART pre-miRNAs which can be further processed into more than 40 mature miR-
NAs [19]. BART-miRNAs are released in a stable form from viable cells enclosed in exosomes
and/or independent of exosomes [20]. Moreover, several BART-miRNAs which are released
into the blood are detected abundantly in NPC patients [21,22]. Thus, BART-miRNAs are new
potential biomarkers for NPC to evaluate the biological activity of viable tumor cells. Although
there have been some reports showing the clinical significance of miRNA at the initial diagno-
sis, no report has shown the significance of detecting circulating BART-miRNAs after treat-
ment to predict the presence of residual tumor cells in NPC patients.
In the current study, we examined the copy numbers of several circulatingBART-miRNAs as
well as BamHI-WDNA before and after treatment, and evaluated their clinical utility as new poten-
tial biomarkers.We selected three of 44 mature BART-miRNAs, miR-BART2-5p, miR-BART17-
5p, andmiR-BART18-5p, which are already known to circulate abundantly in NPC patients [21].
Materials and Methods
Patient characteristics and serum collection
This study was performedwith the approval of the Kanazawa University Ethics Committee
(2015–237). Blood samples were collected from 71 donors after providing written informed
consent from August 2010 to December 2015. For serum collection, venous blood (9 mL) was
collected and placed at room temperature for 1 hour, and then centrifuged at 1,600 g for 10
minutes at 4°C. The serumwas collected gently, aliquoted, and frozen at -80°C until use. Dur-
ing the period, 36 NPC patients were treated at Kanazawa University Hospital and Fukui-ken
Saiseikai Hospital. Among them, thirty-one patients were confirmed as EBV-positive by in situ
hybridization for EBERs. Among the 31 NPC patients, serums at both the initial diagnosis and
three months after treatment were obtained from 20 patients, and serums at three months after
treatment only were obtained from 11 patients (Fig 1). The characteristics of the thirty-one
patients are summarized in Table 1. The characteristics in Table 1 are shown separately for 20
patients with serum at both the initial diagnosis and three months after treatment, and for 11
patients with serums at three months after treatment only. All patients had histologically
proven NPC with clinical stage I to IVC disease using the staging system of the Union Interna-
tionale Contre le Cancer [23]. All these patients had evidence of active disease, thirty as the
first occurrences and one as a recurrence. Twenty-seven of the 31 NPC patients were treated
with alternating chemoradiotherapy, as described in Introduction, and in detail elsewhere [12].
One patient was treated with endoscopic nasopharyngectomy for local relapse of the disease,
which had been treated at another institution [8]. Three patients (two T1N0M0, and one
T4N2M1) were treated with radiotherapy alone.
Blood samples were collected at the initial diagnosis and/or three months after treatment
for NPC patients. Again, among 31 NPC patients, serums at both the initial diagnosis and
three months after treatment were obtained from 20 patients, and serums only at three months
after treatment were obtained from 11 patients. Seven of the thirty-one patients had relapsed,
and four of the thirty-one had a tumor-bearing state at a distant site after treatment. Twenty of
the thirty-one patients maintained complete remission after treatment (Fig 1).
Control samples were obtained from 20 patients admitted to Kanazawa University with non-
NPC head and neck carcinomas (5 oral carcinomas, 5 oropharyngeal carcinomas, 5 hypopharyngeal
carcinomas, and 5 laryngeal carcinomas) at diagnosis, and from 20 healthy volunteers.
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Cell lines, and extractions of DNA and RNA from cells and culture media
Jijoye, a latency type III EBV-positive Burkitt’s lymphoma cell line, and BL2, an EBV-negative
Burkitt’s lymphoma cell line, which were purchased fromDeutsche Sammlung vonMikroorga-
nismen und Zellkulturen (Braunschweig, Germany), were cultured in RPMI-1640 medium
(Thermo Fisher Scientific, Tokyo, Japan) supplemented with 10% fetal bovine serum (Thermo
Fisher Scientific, Tokyo, Japan), and 1% Antibiotic-Antimycotic Mixed stock solution (Nacalai
Tesque, Kyoto, Japan), and were incubated in 5% CO2 at 37°C.
Total DNA and RNA were extracted from Jijoye and BL2 cells, and from each 10 mL of cul-
tured media, respectively. Total DNA and RNA were extracted using the QIAamp DNA Mini
kit (Qiagen, Tokyo, Japan) and RNeasy Plus mini Kit (Qiagen, Tokyo, Japan), according to the
manufacturer’s protocol, respectively.
Extraction of nucleic acids from serum samples
Total nucleic acid was extracted from a 500-μL aliquot of serum by the QIAamp Circulating
Nucleic Acid kit (Qiagen, Tokyo, Japan) following the manufacturer’s protocol. During the
process of nucleic acid extraction, we added synthetic C. elegansmicroRNA, cel-miR-39 (Hok-
kaido System Science, Sapporo, Japan), the so-called spike-in control. Cel-miR-39, which
shows no sequence homology with any human microRNA, was used as an internal control for
Fig 1. Flow chart of 31 NPC patients, with a summary of detection of the circulating BamHI-W DNA and miR-BART17-5p. 36 NPC patients were
treated at Kanazawa University Hospital and Fukui-ken Saiseikai Hospital. Among them, thirty-one patients were confirmed as EBV-positive by in situ
hybridization for EBERs (EBERs-ISH). Among the 31 NPC patients, serums at both the initial diagnosis and three months after treatment were obtained
from 20 patients, and serums at three months after treatment only were obtained from 11 patients. After, 3 months after treatment; Before, before
treatment (at the initial diagnosis); CR, complete remission; EBERs, EBV-encoded small RNAs; EBV, Epstein-Barr virus; and NPC, nasopharyngeal
carcinoma.
doi:10.1371/journal.pone.0163609.g001
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variations during the preparation and recovery of RNA, cDNA synthesis, and real-time qPCR.
Due to a lack of generally accepted standards, all experimental real-time qPCR data for BART-
miRNAs were normalized to cel-miR-39. Finally, it was eluted in 60 μL of DNase/RNase-free
water and stored at -80°C until use. The recovery of RNA extracted from serum samples was
assessed using Bioanalyzer (Agilent Technology, Tokyo, Japan), but the assay did not have
enough sensitivity. Aliquots of nucleic acid for miRNA analyses were treated with RNase-Free
DNase Set (Qiagen, Tokyo, Japan) following the manufacturer’s protocol before use.
Table 1. Clinical characteristics of patients with nasopharyngeal carcinoma.
Number of patients
Characteristics Patients with serum at both initial diagnosis and
after treatment




Total 20 11 31
Sex
male 19 8 27
female 1 3 4
Age
range 16–68 44–81 16–81
mean 56.3 60.1 57.6
Tumor status
T1 7 4 11
T2 3 1 4
T3 6 2 8
T4 4 4 8
Nodal status
N0 4 3 7
N1 5 2 7
N2 7 5 12
N3 4 1 5
Metastasis status
M0 18 9 27
M1 2 2 4
Clinical stage
I 1 1 2
II 2 1 3
III 9 4 13
IVA 4 3 7
IVB 2 0 2
IVC 2 2 4
Histology (WHO Type)








Alternating CRT 18 9 27
Radiotherapy alone 1 2 3
Surgery 1 0 1
CR, complete remission; CRT, chemoradiotherapy; and WHO, World Health Organization. TNM stage classification was based on the staging system of the
Union Internationale Contre Le Cancer [23].
doi:10.1371/journal.pone.0163609.t001
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Construction of a plasmid
We generated a plasmid with 94 bp of BamHI-WDNA inserted. The BamHI-WDNA was
amplified from extractedDNA of an EBV-positive epithelial cell line, NPC-KT cells, by PCR
amplification using KOD FXNeo DNA polymerase (TOYOBO, Osaka, Japan). The primers
used for plasmid constructionwere: 5’-CTGCTAAGCCCAACACTCC-3’ (forward), and
5’-ACCGGTGCCTTCTTAGGAGC-3’ (reverse). The fragment was inserted into the pTA2
vector (TOYOBO, Osaka, Japan).
Reverse transcription
The synthetic miRNA mimics based on the TaqMan MicroRNA Assays list (Applied Biosys-
tems, Tokyo, Japan) were purchased fromHokkaido System Science (Sapporo, Japan). Reverse
transcription (RT) reactions were performed using miRNA-specific looped RT primers of Taq-
Man MicroRNA assays (Applied Biosystems, Tokyo, Japan) and the TaqMan MicroRNA RT
Kit (Applied Biosystems, Tokyo, Japan), according to the Manufacturer’s protocol.
Absolute quantification of BamHI-W DNA-fragment and BART-miRNAs
by real-time qPCR
All qPCR assays were performedwith MX3000P (Agilent Technology Stratagene, Tokyo,
Japan). All tests were duplicated, and all cycle threshold (Ct) values were determinedwith stan-
dard curves in each qPCR. The cut-off Ct values were determined at 40 cycles.
Primers and a probe used to evaluate the copy numbers of BamHI-WDNA-fragment
were: 5’-CTGCTAAGCCCAACACTCC-3’ (forward), 5’-ACCGGTGCCTTCTTAGGAGC-3’
(reverse), and 5’-(FAM)CACACACTACACACACCCACCCGTCTC(TAMRA)-3’ (probe).
Real-time qPCR was performed using Thunderbird Probe qPCRMix (TOYOBO, Osaka,
Japan). A total of 100-fold serial dilutions of the plasmid described above and water as a nega-
tive control were used to generate a standard curve to estimate the absolute copy numbers. The
qPCR cycle conditions were: 95°C for 1 min, then 40 cycles at 95°C for 15 sec, and 60°C for 1
min. According to the protocol of Lin et al., samples with an undetectable EBV signal after pro-
cessing real-time qPCR conditions (40 cycles) were considered to contain zero copies [16].
Each miRNA load was determined by the qPCR assay using the primer sets of TaqMan
MicroRNA Assays (Applied Biosystems, Tokyo, Japan). Real-time qPCR was performed using
TaqMan Universal PCRMaster Mix II w/o UNG (Applied Biosystems, Tokyo, Japan). A total
of 100-fold serial dilutions using cDNA from each synthetic miRNA-mimic by RT reactions, as
described above, and water as a negative control were used to generate each standard curve of
miRNAs to estimate the absolute copy numbers. RT reactions and qPCR assays of the miRNA
mimics were performed in parallel with tested samples. The qPCR cycle conditions were: 95°C
for 10 min, then 40 cycles at 95°C for 15 sec, and 60°C for 1 min.We calculated the recovery
rate based on cel-miR-39 as an exogenous control, and corrected copy numbers of each BART-
miRNA based on this recovery rate. The corrected copy numbers served as each absolute quan-
tity. As well as the BamHI-WDNA-fragment, samples were considered detectable if the ampli-
fication signal occurred before the 40th threshold cycle.
Statistical analyses
The associations of copy numbers of EBV-related DNA and miRNAs with clinical stages were
tested using the Mann-Whitney U test. The Wilcoxon signed rank test was used to test the sig-
nificance of differences between copy numbers before and after treatment. The differences in
copy numbers betweenNPC patients and controls were assessed by the Mann-Whitney U test.
miRNA As a Potential Biomarker to Predict Residual Tumor in NPC
PLOS ONE | DOI:10.1371/journal.pone.0163609 September 29, 2016 6 / 16
We used SPSS statistics 23 software for statistical analyses, and the significancewas defined as
a p-value less than 0.05.
Results
Detection of BamHI-W DNA and BART-miRNAs in EBV-positive and
EBV-negative cell lines
We detected the BamHI-WDNA and three BART-miRNAs in Jijoye cells, a positive control,
but not in BL2 cells, a negative control (Fig 2).
These results suggest that our system could detect these EBV-related DNA and miRNAs
specifically.
Estimating copy numbers of circulating BamHI-W DNA and three BART-
miRNAs in NPC patients at diagnosis and non-NPC controls
Copy numbers of circulating BamHI-WDNA and the three BART-miRNAs for each NPC
patient before and after treatment are summarized in S1 Table. The BamHI-WDNA was
Fig 2. Amplification plots of BamHI-W DNA and three BART-miRNAs extracted from cell lines, by real-time qPCR. (A) BamHI-W DNA; (B) miR-BART2-
5p; (C) miR-BART17-5p; and (D) miR-BART18-5p. Jijoye is a latency type III Epstein-Barr virus-positive Burkitt’s lymphoma cell line, and BL2 is an EBV-
negative Burkitt’s lymphoma cell line. Standard curves are expressed with blue, red, green, grey, and yellow lines using 100-fold serial dilutions of plasmid or
cDNA derived from BART-miRNA mimics. Each amplication plot of Jijoye and BL2 is expressed with purple and orange lines. A horizontal line indicated with an
asterisk (✱) shows the threshold fluorescence based on each standard curve. Amplification plots of Jijoye and BL2 cell lines are indicated with an arrow (➜) and
arrowhead (▲), respectively. Each EBV-related factor was detected only in the positive control, Jijoye, and not in the negative control, BL2.
doi:10.1371/journal.pone.0163609.g002
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detected in 20 of 20 NPC patients at diagnosis. The miR-BART2-5p, miR-BART17-5p, and
miR-BART18-5p were detected in 17, 12, and 5 of the 20 NPC patients, respectively. The detec-
tion of circulating BamHI-WDNA and miR-BART17-5p at the initial diagnosis in 20 NPC
patients are shown in flow chart (Fig 1). The copy numbers of circulating BamHI-WDNA and
the three BART-miRNAs in NPC patients at the initial diagnosis were significantly higher than
those in non-NPC controls (Fig 3). The circulating BamHI-WDNA was not detected in any
non-NPC controls. However, the circulatingmiR-BART2-5p, miR-BART17-5p, and miR-
BART18-5p were detected in 6, 2, and 0 out of 40 patients in the non-NPC controls (20 non-
NPC head and neck carcinomas, and 20 healthy volunteers), respectively (S2 Table).
Fig 3. Copy numbers of circulating BamHI-W DNA and three BART-miRNAs in NPC patients at diagnosis and in non-NPC
controls. (A) BamHI-W DNA; (B) miR-BART2-5p; (C) miR-BART17-5p; and (D) miR-BART18-5p. Serum samples from 20 NPC
patients before treatment and from 40 non-NPC controls (20 non-NPC head and neck carcinomas, and 20 healthy volunteers) were
analyzed. The copy numbers of BamHI-W DNA and the three BART-miRNAs were determined by qPCR and RT-qPCR, respectively.
The copy numbers of BamHI-W DNA and the three BART-miRNAs in NPC patients at diagnosis were significantly higher than those
in non-NPC controls. The copy numbers of BART-miRNAs were corrected by the recovery rate of cel-miR-39, an exogenous spike-in
control. The significance of differences was assessed by the Mann-Whitney U test. The significance was defined as a p-value of less
than 0.05. Circles (⭕) and asterisks (✱) show the statistical outliers, among which asterisks are extreme values. NPC,
nasopharyngeal carcinoma; and HNC, head and neck carcinoma.
doi:10.1371/journal.pone.0163609.g003
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Each sensitivity/specificityof BamHI-WDNA, miR-BART2-5p, miR-BART17-5p, and
miR-BART18-5p for the diagnosis of NPC before treatment were 100 / 100, 85 / 85, 60 / 95,
and 25 / 100%, respectively.
Additionally, for the copy numbers of circulating BamHI-WDNA, there was a significant
difference between stages IV and I-III at diagnosis (Fig 4). In contrast, the copy numbers of the
three BART-miRNAs did not show any significant correlation with the clinical stage at
diagnosis.
Copy numbers of circulating BamHI-W DNA and three BART-miRNAs at
diagnosis and their changes after treatment
Again, the copy numbers of circulating BamHI-WDNA and the three BART-miRNAs for
each NPC patient before and after treatment are summarized in S1 Table. These changes in
copy numbers of BamHI-WDNA and the three BART-miRNAs before and after treatment
Fig 4. Correlation between copy numbers of circulating BamHI-W DNA and three BART-miRNAs, and clinical stage. (A)
BamHI-W DNA; (B) miR-BART2-5p; (C) miR-BART17-5p; and (D) miR-BART18-5p. Classification of clinical stage from stage I to IVC
was based on the staging system of the Union Internationale Contre le Cancer [23]. Twelve NPC patients had stage I-III disease, and 8
had stage IV. The copy numbers of BamHI-W DNA were significantly higher in patients with stage IV disease than in those with stage I-III
disease. None of the three BART-miRNA were correlated with the clinical stage at the initial diagnosis. BART-miRNAs copy numbers
were corrected by the recovery rate of cel-miR-39 as an exogenous spike-in control. The significance of differences was assessed by the
Mann-Whitney U test. The significance was defined as a p-value less than 0.05. Circles (⭕) and asterisks (✱) show the statistical outliers,
among which asterisks are extreme values.
doi:10.1371/journal.pone.0163609.g004
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were analyzed in 20 NPC patients whose serums were obtained at both the initial diagnosis and
three months after treatment. The copy number of BamHI-WDNA significantly decreased
after treatment (p< 0.001) (Fig 5A). No BART-miRNA showed a significant change in copy
numbers after treatment (Fig 5B–5D).
Detection of circulating BamHI-W DNA and BART-miRNAs after
treatment and its association with prognosis in 31 NPC patients
A summary of the detection of circulating BamHI-WDNA and BART-miRNAs after treat-
ment and its association with the prognosis in 31 NPC patients are shown in S3 Table. Among
11 patients with relapse or residual disease, the circulating BamHI-WDNA-fragment was
detectable in 5 patients. Two relapsed later, and three had distant metastasis before and after
treatment. In contrast, no circulating BamHI-WDNA-fragment was detected in the 20 patients
maintaining remission. The miR-BART17-5p was detected in 6 out of 11 patients with relapse
or residual disease after treatment; 3 of them were newly detected cases after treatment. Four of
the 6 patients relapsed later, and two were patients who had consistently shown distant metas-
tasis since the initial diagnosis. Thus, these 6 miR-BART17-5p-detectable NPC patients after
Fig 5. Copy numbers of circulating BamHI-W DNA and three BART-miRNAs at diagnosis and changes after treatment. The copy
numbers of circulating BamHI-W DNA and the three BART-miRNAs were analyzed in serums from 20 patients with NPC before and three
months after treatment. (A) The copy numbers of BamHI-W DNA before treatment were significantly decreased three months after treatment. (B)
miR-BART2-5p; (C) miR-BART17-5p; and (D) miR-BART18-5p. No significant change in the copy number of any BART-miRNA was found. The
change in copy number before and after treatment was linked in a line for each patient. BART-miRNA copy numbers were corrected by the
recovery rate of cel-miR-39 as an exogenous spike-in control. The significance of differences was assessed by the Wilcoxon test. The
significance was defined as a p-value less than 0.05.
doi:10.1371/journal.pone.0163609.g005
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treatment all showed a tumor-bearing state. No circulatingmiR-BART17-5p was detected in
any of the 20 patients maintaining remission. The detection of circulating BamHI-WDNA
and miR-BART17-5p after treatment and its association with the prognosis of 31 NPC patients
are summarized in Fig 1. The miR-BART18-5p was detected in only 2 of the 31 NPC patients
after treatment. The 2 patients with elevated miR-BART18-5p loads after treatment developed
distant metastases. The miR-BART 2-5p was still detected in 25 of the 31 NPC patients after
treatment.
Discussion
In the current study, the detection of serumBamHI-WDNA yielded both 100% sensitivity and
specificity for the initial diagnosis of patients with NPC, which are comparable to past reports
[14]. The sensitivity and specificity of miR-BART2-5p, miR-BART17-5p, and miR-BART18-
5p were limited to 85 / 85, 60 / 95, and 25 / 100% for NPC at diagnosis, respectively. Thus,
quantified copy numbers of the EBV-DNA provided a more useful biomarker for the diagnosis
of NPC before treatment than the BART-miRNAs examined. The copy numbers of the DNA
fragment were positively associated with the clinical stage of the disease at diagnosis. These
results suggest that the serumEBV-DNA load detected by qPCR was correlated with the tumor
volume. Actually, copy numbers of BamHI-WDNA in serumwere markedly decreased after
treatment. These data are compatible with previous reports showing the insufficient sensitivity
of the EBV-DNA load in stage I NPC (50–86%) [14]. Although the origin of the circulating
EBV-DNA detected by qPCR has been reported to be that derived from tumor apoptosis or
necrosis shed into the blood stream [14], circulating viral RNAs would be derived from viable
tumor cells via active extracellular transport. The copy numbers of these BART-miRNAs
examined in the current study were not significantly correlated with the clinical stage at diag-
nosis. In addition, no significant changes in the copy numbers of any circulating BART-miR-
NAs were found after treatment. These data show that copy numbers of these circulating
BART-miRNAs are affected by the activity in the production and/or secretion of thesemiRNAs
from viable tumor cells rather than the tumor volume as BamHI-WDNA. Thus, the circulating
BART-miRNAs may be biomarkers playing important roles in monitoring these activities of
viable tumor cells regardless of the tumor volume.
The circulatingmiR-BART2-5p was still detected in 25 of the 31 NPC patients at 3 months
after treatment. The circulatingmiR-BART18-5p was detected in only 2 of the 11 patients with
relapse or residual disease. These data show that miR-BART2-5p and miR-BART18-5p are not
favorable candidate biomarkers with high sensitivity and/or specificity after treatment to make
a prognosis. At 3 months after treatment, the BamHI-WDNA was detected in 5 of the 11 NPC
patients with relapse or residual diseases, and the EBV-DNA was not detected in the 20 cases
with remission. The circulatingmiR-BART17-5p was detected in 6 of the 11 patients with
relapse or residual tumors, whereas the miRNA was not detected in any of the 20 patients with
remission. These results suggest that the detection of circulatingmiR-BART17-5p after treat-
ment is a candidate biomarker at least comparable to those of BamHI-WDNA to predict treat-
ment outcomes, and, thus, to select patients for adjuvant chemotherapy. In the previous two
reports, patients with recurrencemaintained high post-treatment EBV-DNA-positive rates of
90 and 63%, respectively [24,25]. In the current study, the EBV-DNA-positive rate in patients
with relapse or residual disease at three months after treatment was 45% (5 out of 11), which
was lower compared with these reports. In a review of the literature on the qPCR protocol to
measure copy numbers of circulating EBV-DNA, Yip et al. showed that plasma gives a higher
sensitivity than serum in the optimal experimental protocol, although the specificity remains
the same [14]. If we had used plasma instead of serum after treatment, a higher sensitivity of
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EBV-DNA might have been obtained. For miR-BART17-5p, Gourzones et al. detected circulat-
ing miRNA in 10 out of 10 control donors using plasma samples and qPCR with 45 cycle [26].
In contrast, miR-BART17-5p was detected in 2 out of 40 control donors using serum and
qPCR with 40 cycles in our current study. It is a problem that there is not a common protocol
to measure these circulatingDNAs and RNAs. The protocols should be established and unified
to an optimal protocol in the future to compare these controversial results derived from differ-
ent protocols.
CirculatingmiRNAs in malignant diseases are being actively investigated, and large
amounts of data have already been published [26,27,28]. One remarkable characteristic of cir-
culatingmiRNAs is their stability. To a large extent, the stability of circulatingmiRNAs results
from their associations with various types of carriers [29]. BART-miRNAs packaged into exo-
somes have sufficient stability and motility to reach the circulating blood [22,29,30]. Interest-
ingly, circulatingmiR-BART17-5p is co-purifiedwith a protein-rich fraction but not with
exosomes, which suggests the non-exosomal transport of miR-BART17-5p [26]. Arroyo et al.
found that the majority of circulatingmiRNAs were cofractionatedwith protein complexes
rather than with vesicles, and the majority of miRNAs studied were copurifiedwith the Argo-
naute (AGO) 2 ribonucleoprotein complex [31]. In addition, AGO2 over-expression is a risk
factor for advanced lymph nodemetastasis, and it can contribute to malignant behavior in
NPC [32]. Therefore, it would be interesting to examine whethermiR-BART17-5p can be
immunoprecipitated with anti-AGO2 antibodies.
At least in 4 of the 11 recurrent or residual cases, the copy numbers of circulatingmiR--
BART17-5p were increased from undetectable to detectable levels after treatment (S1 Table.
Case 2, 3, 6, and 8). Although the mechanism of increase in miR-BART17-5p remains to be
clarified in a future study, the changes in expression patterns of miRNAs by cancer treatment
modalities such as radiotherapy and/or chemotherapy are being increasingly recognized. It has
been shown in cancer cells that the expression of miRNAs may vary depending on parameters
like the cell type, post-radiation time, and radiation dose [33,34,35]. The changes in expression
profiles of miRNAs might also be observed in NPC after radiotherapy and/or chemotherapy.
As miR-BART17-5p is released by an exosome-independentmechanism, the increase of circu-
lating miR-BART17-5p might indicate a change in the secretory phenotype of NPC cells from
exosome-dependent to exosome-independent after chemoradiotherapy. These are compatible
with the hypotheses of Arroyo et al., in which vesicle-associated versus AGO2 complex-associ-
ated miRNAs originate from different cell types and reflect a cell-type-specificmiRNA expres-
sion and/or release mechanism [31].
It has been shown that miR-BART17-5p can target the 3’UTR of the LMP1 gene and nega-
tively regulate the appropriate expression of the protein. miR-BART17-5p also modulates the
LMP1-inducedNF-κB signal transduction pathway and alleviates the cisplatin sensitivity of
LMP1-expressing NPC cells [36]. High-level LMP1 inhibits cell growth and causes apoptosis,
while low-level LMP1 promotes the growth and survival of these cells [20]. Indeed, miR--
BART17-5p may devote a function of LMP1 to the cancer promotion side by targeting LMP1.
In addition, miR-BART17-5p activates theWnt pathway by down-regulatingWnt inhibitory
genes, APC [21,37,38]. These data suggest that miR-BART17-5p helps transform the proapop-
totic phenotype of LMP1-positive NPC cells to a surviving and chemo-resistant phenotype.
The role of miR-BART17-5p in survivingNPC cells after chemotherapy and/or radiotherapy
should be clarified in the future.
Some reports showed that non-EBV-related miRNAs may be biomarkers for the diagnosis
of and prognosis associated with NPC [39,40,41]. Although these miRNAs were useful bio-
markers at the initial diagnosis, it is unknownwhether they are reliable biomarkers predicting
recurrence and/or residual tumors after treatment. For EBV-related miRNAs, Zhang et al.
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reported that miR-BART7 and miR-BART13 are biomarkers not only for NPC diagnosis, but
also for estimating the effect of therapy after treatment [15]. Although they showed that these
EBV-related miRNAs are significantly decreased after treatment, they did not assess the corre-
lation between the copy numbers of these miRNAs after treatment and the prognosis of each
patient. Although our current report presents data from a pilot study, this is the first report to
propose the clinical significance of quantifying copy numbers of EBV-specific miRNAs to esti-
mate residual tumor cells after treatment in NPC patients.
In summary, circulating BamHI-WDNA was a useful biomarker for the diagnosis of NPC
before treatment. The detection of circulatingmiR-BART17-5p after treatment was considered
as a candidate potential biomarker to predict a poor treatment outcome. In the current study,
the case number was too limited to arrive at a definite conclusion. However, the data shown in
this study are encouraging to test whether the quantitative analysis of circulatingmiR--
BART17-5p, an exosome-independent secretory EBV-associated miRNA, is a reliable potential
biomarker to predict the treatment outcome with larger sample sizes in future studies.
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5p, andmiR-BART18-5p in non-NPC controls.
(XLS)




Financial support was provided by a grant from the Ministry of Education, Science, Sports,
Culture and Technology of Japan (15K20190 and 26462597). We thank Drs Taeko Tanaka and
Yoshinori Shimizu for cooperationwith collecting samples.
Author Contributions
Conceptualization:NWTY.









miRNA As a Potential Biomarker to Predict Residual Tumor in NPC
PLOS ONE | DOI:10.1371/journal.pone.0163609 September 29, 2016 13 / 16
Visualization:NH YN SM.
Writing – original draft:NHNW.
Writing – review& editing:NWTY.
References
1. Ho JH (1978) An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol
Biol Phys 4: 182–198. doi: 10.1016/0360-3016(78)90137-2 PMID: 640889
2. Kimura Y, Suzuki D, Tokunaga T, Takabayashi T, Yamada T, Wakisaka N, et al. (2011) Epidemiologi-
cal analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to
2005. Auris Nasus Larynx 38: 244–249. doi: 10.1016/j.anl.2010.07.006 PMID: 20817430
3. Wang DC, Cai WM, Hu YH, Gu XZ (1988) Long-term survival of 1035 cases of nasopharyngeal carci-
noma. Cancer 61: 2338–2341. doi: 10.1002/1097-0142(19880601)61:11%3C2338::aid-
cncr2820611131%3E3.0.co;2-o PMID: 3365661
4. Thompson LDR (2007) Update on Nasopharyngeal Carcinoma. Head and Neck Pathology 1: 81–86.
doi: 10.1007/s12105-007-0012-7 PMID: 20614287
5. Raab-Traub N (2012) Novel mechanisms of EBV-induced oncogenesis. Current Opinion in Virology 2:
453–458. doi: 10.1016/j.coviro.2012.07.001 PMID: 22858118
6. Yoshizaki T, Kondo S, Murono S, Endo K, Tsuji A, Nakanishi Y, et al. (2015) Progress and controversy
for the role of chemotherapy in nasopharyngeal carcinoma. Japanese Journal of Clinical Oncology 45:
244–247. doi: 10.1093/jjco/hyu212 PMID: 25583421
7. Yoshizaki T, Kondo S, Wakisaka N, Murono S, Endo K, Sugimoto H, et al. (2013) Pathogenic role of
Epstein–Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinoma. Can-
cer Letters 337: 1–7. doi: 10.1016/j.canlet.2013.05.018 PMID: 23689138
8. Yoshizaki T, Wakisaka N, Murono S, Shimizu Y, Furukawa M (2005) Endoscopic nasopharyngectomy
for patients with recurrent nasopharyngeal carcinoma at the primary site. Laryngoscope 115: 1517–
1519. doi: 10.1097/01.MLG.0000165383.35100.17 PMID: 16094136
9. Mesic JB, Fletcher GH, Goepfert H (1981) Megavoltage irradiation of epithelial tumors of the nasophar-
ynx. Int J Radiat Oncol Biol Phys 7: 447–453. doi: 10.1016/0360-3016(81)90129-2 PMID: 6788731
10. Wang CC, Meyer JE (1971) Radiotherapeutic management of carcinoma of the nasopharynx. An anal-
ysis of 170 patients. Cancer 28: 566–570. doi: 10.1002/1097-0142(197109)28:3%3C566::aid-
cncr2820280306%3E3.0.co;2-a PMID: 5096921
11. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vung T, et al. (1998) Chemoradiotherapy versus
radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study
0099. J Clin Oncol 16: 1310–1317. PMID: 9552031
12. Fuwa N, Kodaira T, Daimon T, Yoshizaki T (2015) The long-term outcomes of alternating chemora-
diotherapy for locoregionally advanced nasopharyngeal carcinoma: a multiinstitutional phase II study.
Cancer Medicine 4: 1186–1195. doi: 10.1002/cam4.469 PMID: 25991077
13. Yoshizaki T, Endo K, Ren Q, Wakisaka N, Murono S, Kondo S, et al. (2007) Oncogenic role of Epstein-
Barr virus-encoded small RNAs (EBERs) in nasopharyngeal carcinoma. Auris Nasus Larynx 34: 73–
78. doi: 10.1016/j.anl.2006.09.025 PMID: 17129696
14. Yip TTC, Ngan RKC, Fong AHW, Law SCK (2014) Application of circulating plasma/serum EBV DNA
in the clinical management of nasopharyngeal carcinoma. Oral Oncology 50: 527–538. doi: 10.1016/j.
oraloncology.2013.12.011 PMID: 24440146
15. Zhang G, Zong J, Lin S, Verhoeven RJA, Tong S, Chen Y, et al. (2015) Circulating Epstein-Barr virus
microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis
and treatment. International Journal of Cancer 136: E301–E312. doi: 10.1002/ijc.29206 PMID:
25213622
16. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. (2004) Quantification of plasma
Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350:
2461–2470. doi: 10.1056/NEJMoa032260 PMID: 15190138
17. Kondo S, Horikawa T, Takeshita H, Kanegane C, Kasahara Y, Sheen TS, et al. (2004) Diagnostic
value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carci-
noma patients. Cancer Sci 95: 508–513. doi: 10.1111/j.1349-7006.2004.tb03241.x PMID: 15182432
18. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, et al. (2004) Identification of virus-encoded
microRNAs. Science 304: 734–736. doi: 10.1126/science.1096781 PMID: 15118162
miRNA As a Potential Biomarker to Predict Residual Tumor in NPC
PLOS ONE | DOI:10.1371/journal.pone.0163609 September 29, 2016 14 / 16
19. Klinke O, Feederle R, Delecluse HJ (2014) Genetics of Epstein-Barr virus microRNAs. Semin Cancer
Biol 26: 52–59. doi: 10.1016/j.semcancer.2014.02.002 PMID: 24602823
20. Lo AKF, Dawson CW, Jin D-Y, Lo K-W (2012) The pathological roles of BART miRNAs in nasopharyn-
geal carcinoma. The Journal of Pathology 227: 392–403. doi: 10.1002/path.4025 PMID: 22431062
21. Wong AMG, Kong KL, Tsang JWH, Kwong DLW, Guan X-Y (2012) Profiling of Epstein-Barr virus-
encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Can-
cer 118: 698–710. doi: 10.1002/cncr.26309 PMID: 21720996
22. Gourzones C, Gelin A, Bombik I, Klibi J, Ve´rillaud B, Guigay J, et al. (2010) Extra-cellular release and
blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells.
Virology Journal 7: 271. doi: 10.1186/1743-422X-7-271 PMID: 20950422
23. Sobin LH, Gospodarowicz MK, Wittekind Ch (2009) TNM classification of malignant tumours. New
York: Wiley-Blackwell. 30–38 p.
24. Leung SF, Lo YM, Chan AT, To KF, To E, Chan LY, et al. (2003) Disparity of sensitivities in detection
of radiation-naive and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type
by quantitative analysis of circulating Epstein-Barr virus DNA1,2. Clin Cancer Res 9: 3431–3434.
PMID: 12960133
25. Liang FY, Sun W, Han P, Lu X, Lian YN, Huang XM (2012) Detecting plasma Epstein-Barr virus DNA
to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a
prospective study. Chin J Cancer 31: 142–149. doi: 10.5732/cjc.011.10279 PMID: 22237037
26. Gourzones C, Ferrand FR, Amiel C, Verillaud B, Barat A, Guerin M, et al. (2013) Consistent high con-
centration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients
—evidence of non-exosomal transport. Virology Journal 10: 119. doi: 10.1186/1743-422X-10-119
PMID: 23590857
27. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA, et al. (2011) Micro-
RNAs in body fluids—the mix of hormones and biomarkers. Nature Reviews Clinical Oncology 8: 467–
477. doi: 10.1038/nrclinonc.2011.76 PMID: 21647195
28. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. (2008) Circu-
lating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National
Academy of Sciences 105: 10513–10518. doi: 10.1073/pnas.0804549105 PMID: 18663219
29. Principe S, Hui AB-Y, Bruce J, Sinha A, Liu F-F, Kislinger T, et al. (2013) Tumor-derived exosomes
and microvesicles in head and neck cancer: Implications for tumor biology and biomarker discovery.
Proteomics 13: 1608–1623. doi: 10.1002/pmic.201200533 PMID: 23505015
30. Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B (2009) The microRNAs of Epstein–Barr Virus are
expressed at dramatically differing levels among cell lines. Virology 386: 387–397. doi: 10.1016/j.virol.
2009.01.006 PMID: 19217135
31. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. (2011) Argonaute2 com-
plexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc
Natl Acad Sci U S A 108: 5003–5008. doi: 10.1073/pnas.1019055108 PMID: 21383194
32. Li P, Meng J, Zhai Y, Zhang H, Yu L, Wang Z, et al. (2015) Argonaute 2 and nasopharyngeal carci-
noma: a genetic association study and functional analysis. BMC Cancer 15: 862. doi: 10.1186/
s12885-015-1895-4 PMID: 26545861
33. Ishii H, Saito T (2006) Radiation-induced response of micro RNA expression in murine embryonic
stem cells. Med Chem 2: 555–563. doi: 10.2174/1573406410602060555 PMID: 17105436
34. Wagner-Ecker M, Schwager C, Wirkner U, Abdollahi A, Huber PE (2010) MicroRNA expression after
ionizing radiation in human endothelial cells. Radiation Oncology 5: 25. doi: 10.1186/1748-717X-5-25
PMID: 20346162
35. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, et al. (2007) MicroRNAs as Potential
Agents to Alter Resistance to Cytotoxic Anticancer Therapy. Cancer Research 67: 11111–11116. doi:
10.1158/0008-5472.CAN-07-2858 PMID: 18056433
36. Lo AKF, To KF, Lo KW, Lung RWM, Hui JWY, Liao G, et al. (2007) Modulation of LMP1 protein expres-
sion by EBV-encoded microRNAs. Proceedings of the National Academy of Sciences 104: 16164–
16169. doi: 10.1073/pnas.0702896104 PMID: 17911266
37. Xie Y-J, Long Z-F, He X-S (2013) Involvement of EBV-encoded BART-miRNAs and Dysregulated Cel-
lular miRNAs in Nasopharyngeal Carcinoma Genesis. Asian Pacific Journal of Cancer Prevention 14:
5637–5644. PMID: 24289555
38. Webb N, Connolly G, Tellam J, Yap AS, Khanna R (2008) Epstein-Barr virus associated modulation of
Wnt pathway is not dependent on latent membrane protein-1. PLoS One 3: e3254. doi: 10.1371/
journal.pone.0003254 PMID: 18806872
miRNA As a Potential Biomarker to Predict Residual Tumor in NPC
PLOS ONE | DOI:10.1371/journal.pone.0163609 September 29, 2016 15 / 16
39. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, et al. (2012) Prognostic value of a microRNA signature
in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 13: 633–641. doi: 10.
1016/S1470-2045(12)70102-X PMID: 22560814
40. Peng D, Zeng X, Xiang J, Wu M, Xiong W, Tang H, et al. (2012) Circulating miR-17, miR-20a, miR-
29c, and miR-223 Combined as Non-Invasive Biomarkers in Nasopharyngeal Carcinoma. PLoS One
7: e46367. doi: 10.1371/journal.pone.0046367 PMID: 23056289
41. Wang HY, Yan LX, Shao Q, Fu S, Zhang ZC, Ye W, et al. (2014) Profiling Plasma MicroRNA in Naso-
pharyngeal Carcinoma with Deep Sequencing. Clinical Chemistry 60: 773–782. doi: 10.1373/
clinchem.2013.214213 PMID: 24563490
miRNA As a Potential Biomarker to Predict Residual Tumor in NPC
PLOS ONE | DOI:10.1371/journal.pone.0163609 September 29, 2016 16 / 16
